ストックスクリーナーアプリを入手
2.83
16.94%
0.41
アフターアワーズ：
2.83
前日終値:
$2.42
開ける：
$2.49
24時間の取引高:
356.38K
Relative Volume:
1.12
時価総額：
$46.38M
収益：
-
当期純損益:
$-94.11M
株価収益率:
-0.4709
EPS:
-6.01
ネットキャッシュフロー:
$-86.06M
1週間 パフォーマンス:
+27.48%
1か月 パフォーマンス:
-12.38%
6か月 パフォーマンス:
-52.12%
1年 パフォーマンス:
-62.01%
1日の値動き範囲:
$2.475
$2.83
1週間の範囲:
$2.23
$2.83
52週間の値動き範囲:
$1.78
$10.14
Adverum Biotechnologies Inc Stock (ADVM) Company Profile
名前
Adverum Biotechnologies Inc
セクター
電話
(650) 649-1004
住所
100 CARDINAL WAY, REDWOOD CITY, CA
ADVM を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ADVM
Adverum Biotechnologies Inc
|
2.83 | 46.38M | 0 | -94.11M | -86.06M | -6.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Adverum Biotechnologies Inc Stock (ADVM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-06-25 | 開始されました | Oppenheimer | Outperform |
| 2024-04-30 | 開始されました | H.C. Wainwright | Buy |
| 2022-07-07 | アップグレード | Truist | Hold → Buy |
| 2021-07-23 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2021-05-03 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2021-04-29 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2021-04-29 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-04-29 | ダウングレード | Truist | Buy → Hold |
| 2020-12-16 | 開始されました | UBS | Neutral |
| 2020-11-12 | アップグレード | Raymond James | Underperform → Mkt Perform |
| 2020-06-26 | ダウングレード | Raymond James | Mkt Perform → Underperform |
| 2020-05-13 | 開始されました | RBC Capital Mkts | Outperform |
| 2020-05-05 | アップグレード | SunTrust | Hold → Buy |
| 2020-04-28 | 開始されました | Goldman | Buy |
| 2020-03-16 | 開始されました | SVB Leerink | Outperform |
| 2020-02-10 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2020-02-10 | アップグレード | Chardan Capital Markets | Neutral → Buy |
| 2019-10-15 | 繰り返されました | Chardan Capital Markets | Neutral |
| 2019-09-13 | 繰り返されました | Chardan Capital Markets | Neutral |
| 2019-06-14 | 再開されました | Raymond James | Mkt Perform |
| 2018-11-02 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2018-11-02 | ダウングレード | SunTrust | Buy → Hold |
| 2018-09-21 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-08-30 | 開始されました | SunTrust | Buy |
| 2018-02-15 | 再開されました | Piper Jaffray | Overweight |
| 2017-10-12 | 開始されました | Raymond James | Outperform |
すべてを表示
Adverum Biotechnologies Inc (ADVM) 最新ニュース
Adverum Biotechnologies (NASDAQ:ADVM) versus Metagenomi (NASDAQ:MGX) Head-To-Head Analysis - Defense World
Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Adverum Awards 14,610 Shares in Stock Options and RSUs to Key New Hires - Stock Titan
Adverum Biotechnologies Reports Q1 2025 Financial Results - TipRanks
Adverum Biotechnologies (ADVM) Sees Price Target Adjustment by RBC Capital | ADVM Stock News - GuruFocus
Adverum Biotechnologies (ADVM) Receives Continued Buy Rating from Chardan Capital | ADVM Stock News - GuruFocus
Adverum Biotechnologies (ADVM) Price Target Reduced by RBC Capit - GuruFocus
Adverum Biotechnologies (ADVM) Rating Reiterated at 'Buy' by HC Wainwright | ADVM Stock News - GuruFocus
RBC Cuts Price Target on Adverum Biotechnologies to $4 From $5, Keeps Sector Perform, Speculative Risk - marketscreener.com
Adverum Biotechnologies: Q1 Earnings Snapshot - CT Insider
Adverum (ADVM) Projects Funding Through Late 2025 | ADVM Stock N - GuruFocus
Adverum Biotechnologies Reports First Quarter 2025 Financial Results and Provides Pipeline Highlights - The Manila Times
Adverum Biotechnologies Reports First Quarter 2025 Financial Results and Provides Pipeline ... - Bluefield Daily Telegraph
Revolutionary One-Time Gene Therapy Shows 3.5-Year Vision Protection in Wet AMD Patients - Stock Titan
Adverum Biotechnologies Inc (ADVM)’s Market Momentum: Closing Strong at 3.23, Down -10.03 - DWinneX
Adverum Biotechnologies’ SWOT analysis: gene therapy firm faces pivotal year - Investing.com Nigeria
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc.ADVM - PR Newswire
Adverum Biotechnologies' SWOT analysis: gene therapy firm faces pivotal year - Investing.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum ... - Bluefield Daily Telegraph
Adverum Biotechnologies Inc expected to post a loss of $1.94 a shareEarnings Preview - TradingView
Adverum Biotechnologies Awards Strategic Stock Options Worth $108,000 to Expand Team - Stock Titan
It makes sense and dollars to buy Adverum Biotechnologies Inc (ADVM) stock - Sete News
Adverum Biotechnologies Inc: Navigating Market Volatility with a 1.79 Debt-to-Equity Ratio - investchronicle.com
Adverum Biotechnologies Inc [ADVM] Investment Guide: What You Need to Know - knoxdaily.com
Should investors be concerned about Adverum Biotechnologies Inc (ADVM)? - uspostnews.com
Gaining Ground: Adverum Biotechnologies Inc (ADVM) Closes Lower at 2.91, Down -2.02 - DWinneX
Press Release Distribution & PR Platform - ACCESS Newswire
Hedge Fund and Insider Trading News: Ken Griffin, Steve Cohen, Scott Bessent, Balyasny Asset Management, Bridgewater Associates, Starboard Value, Maverick Capital, Kodai Capital Management, Antara Capital, Adverum Biotechnologies Inc (ADVM), and - Insider Monkey
Adverum Biotechnologies Insider Bought Shares Worth $1,048,950, According to a Recent SEC Filing - marketscreener.com
Adverum Biotechnologies Insider Buys 350,000 Shares - TradingView
Adverum Biotechnologies Inc (ADVM) is an excellent investment, but the stock is overvalued/undervalued right now - uspostnews.com
Trading Day Triumph: Adverum Biotechnologies Inc (ADVM) Ends at 2.96, a 8.42 Surge/Plunge - DWinneX
Bronstein, Gewirtz & Grossman, LLC Encourages Adverum Biotechnologies, Inc. (ADVM) Stockholders to Inquire about Securities Investigation - markets.businessinsider.com
Truist Removes $40 Price Target on Adverum Biotechnologies, Cites Share Volatility, Keeps Buy Rating - marketscreener.com
Bronstein, Gewirtz & Grossman, LLC Encourages Adverum Biotechnologies, Inc. (ADVM) Investors to Inquire about Securities Investigation - markets.businessinsider.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Adverum Biotechnologies, Inc. (ADVM) And Encourages Investors to Reach Out - markets.businessinsider.com
Adverum Biotechnologies (NASDAQ:ADVM) Earns Buy Rating from HC Wainwright - Defense World
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Adverum Biotechnologies, Inc. (ADVM) And Encourages Stockholders to Reach Out - markets.businessinsider.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - GlobeNewswire Inc.
Intuit To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Thursday - Benzinga
Bronstein, Gewirtz & Grossman, LLC Is Investigating Adverum Biotechnologies, Inc. (ADVM) And Encourages Stockholders to Connect - markets.businessinsider.com
RBC Cuts Price Target on Adverum Biotechnologies to $5 From $10, Keeps Sector Perform, Speculative Risk - marketscreener.com
Adverum Biotechnologies Reports 2024 Financial Results and Pipeline Progress - TipRanks
Adverum Biotechnologies Inc (ADVM) 財務データ
収益
当期純利益
現金流量
EPS
1.21%
1.51%
大文字化:
|
ボリューム (24 時間):